L-抗坏血酸钠  分析标准品

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
熔点:220 °C
包装规格:250mg in glass bottle
产品简介:细胞培养,还原剂,抗氧剂。
溶解性:Water:溶于水
储备液保存:-80°C, 6 months; -20°C, 1 month。 (sealed storage, away from moisture and light)
体内实验:1、请依序添加每种溶剂: PBS Solubility: 50 mg/mL (252.39 mM); 澄清溶液; 超声助溶 注:工作液建议您现用现配,在短期内尽快用完。 <1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
靶点:T-type calcium channel;Microbial Metabolite
体外研究:The conditioned medium for B16F10 cells significantly inhibits cell apoptosis induced by L-Ascorbic acid sodium salt (Sodium L-ascorbate) (10 mM), and the effective ingredients in the Medium show a relative molecular mass below 5,000.
体内研究:Tg rats treated with L-Ascorbic acid sodium salt (Sodium L-ascorbate) show a higher incidence of carcinoma (29.6%), compared to those without L-Ascorbic acid sodium salt (15.4%). Independent of the L-Ascorbic acid sodium salt treatment, transgenic rats exhibit various kinds of malignant tumors in various organs. After 12 weeks of PEITC-treatment, both simple hyperplasia and papillary or nodular (PN)hyperplasia have developed in all animals, but the majority of these lesions have disappeared at week 48, irrespective of the L-Ascorbic acid sodium salt-treatment. The same lesions after 24 weeks of PEITC-treatment have progressed to dysplasia and carcinoma, in a small number of cases by week 48, but enhancement by the L-Ascorbic acid sodium salt-treatment is evident only with simple hyperplasias and PN hyperplasias in rats.
保存条件:室温
注意事项:1、为了您的安全和健康,请穿实验服并戴一次性手套操作。 2、以上信息仅做参考交流之用。